白三烯抑制剂作为儿童支气管哮喘的基础治疗

Zebo Norboboevna Sherova, KamolaYuldashevna Normatova, Kamala Shakhamdamovna Shaabidova
{"title":"白三烯抑制剂作为儿童支气管哮喘的基础治疗","authors":"Zebo Norboboevna Sherova, KamolaYuldashevna Normatova, Kamala Shakhamdamovna Shaabidova","doi":"10.48112/acmr.v3i2.31","DOIUrl":null,"url":null,"abstract":"In the pharmacotherapy of bronchial asthma, a \"step-by-step\" approach is recommended, which includes an increase or decrease in the volume of therapy, depending on the severity of clinical symptoms. In complex therapy, it is possible to use non-drug methods of treatment, although the effectiveness of some of them is debatable and needs further study. To achieve this goal, children over the age of 3 years (the group of patients consisted of 26 children) with different forms and degrees of severity of bronchial asthma were included in the study. Patients of the main group took L-Montus (montelukast), children of the ketotifen comparison group. Leukotriene receptor antagonists (montelukast, zafirlukast) are the first mediator-specific therapy of AD and represent a new therapeutic class of drugs in the treatment of the disease. The effectiveness of leukotriene receptor antagonists has been proven in randomized clinical trials among adults and children with bronchial asthma. Leukotriene receptor blockers, in particular L-Montus relieves the symptoms of AD and is a drug for the basic therapy of this disease, leads to a significant improvement in control, reduces the frequency of exacerbations of AD caused by viral infection in children aged 3-5 years. It has an anti-inflammatory effect, complementary to the action of glucocorticosteroids.","PeriodicalId":7266,"journal":{"name":"Advances in Clinical Medical Research and Healthcare Delivery","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Use of Leukotriene Inhibitors as Basic Therapy in Children with Bronchial Asthma\",\"authors\":\"Zebo Norboboevna Sherova, KamolaYuldashevna Normatova, Kamala Shakhamdamovna Shaabidova\",\"doi\":\"10.48112/acmr.v3i2.31\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the pharmacotherapy of bronchial asthma, a \\\"step-by-step\\\" approach is recommended, which includes an increase or decrease in the volume of therapy, depending on the severity of clinical symptoms. In complex therapy, it is possible to use non-drug methods of treatment, although the effectiveness of some of them is debatable and needs further study. To achieve this goal, children over the age of 3 years (the group of patients consisted of 26 children) with different forms and degrees of severity of bronchial asthma were included in the study. Patients of the main group took L-Montus (montelukast), children of the ketotifen comparison group. Leukotriene receptor antagonists (montelukast, zafirlukast) are the first mediator-specific therapy of AD and represent a new therapeutic class of drugs in the treatment of the disease. The effectiveness of leukotriene receptor antagonists has been proven in randomized clinical trials among adults and children with bronchial asthma. Leukotriene receptor blockers, in particular L-Montus relieves the symptoms of AD and is a drug for the basic therapy of this disease, leads to a significant improvement in control, reduces the frequency of exacerbations of AD caused by viral infection in children aged 3-5 years. It has an anti-inflammatory effect, complementary to the action of glucocorticosteroids.\",\"PeriodicalId\":7266,\"journal\":{\"name\":\"Advances in Clinical Medical Research and Healthcare Delivery\",\"volume\":\"6 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-06-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Clinical Medical Research and Healthcare Delivery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.48112/acmr.v3i2.31\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Clinical Medical Research and Healthcare Delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48112/acmr.v3i2.31","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

在支气管哮喘的药物治疗中,建议采用“循序渐进”的方法,包括根据临床症状的严重程度增加或减少治疗量。在复杂的治疗中,可以使用非药物治疗方法,尽管其中一些方法的有效性值得商榷,需要进一步研究。为实现这一目标,研究纳入了不同形式和严重程度支气管哮喘的3岁以上儿童(患者组26例)。主组患者服用孟鲁司特(L-Montus,孟鲁司特),对照组患儿服用酮替芬。白三烯受体拮抗剂(孟鲁司特,扎非鲁司特)是AD的第一个介质特异性治疗药物,代表了治疗该疾病的新治疗类药物。白三烯受体拮抗剂的有效性已在支气管哮喘成人和儿童的随机临床试验中得到证实。白三烯受体阻滞剂,特别是L-Montus,可缓解AD的症状,是AD的基础治疗药物,可显著改善AD的控制,降低3-5岁儿童因病毒感染引起AD加重的频率。它具有抗炎作用,与糖皮质激素的作用互补。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The Use of Leukotriene Inhibitors as Basic Therapy in Children with Bronchial Asthma
In the pharmacotherapy of bronchial asthma, a "step-by-step" approach is recommended, which includes an increase or decrease in the volume of therapy, depending on the severity of clinical symptoms. In complex therapy, it is possible to use non-drug methods of treatment, although the effectiveness of some of them is debatable and needs further study. To achieve this goal, children over the age of 3 years (the group of patients consisted of 26 children) with different forms and degrees of severity of bronchial asthma were included in the study. Patients of the main group took L-Montus (montelukast), children of the ketotifen comparison group. Leukotriene receptor antagonists (montelukast, zafirlukast) are the first mediator-specific therapy of AD and represent a new therapeutic class of drugs in the treatment of the disease. The effectiveness of leukotriene receptor antagonists has been proven in randomized clinical trials among adults and children with bronchial asthma. Leukotriene receptor blockers, in particular L-Montus relieves the symptoms of AD and is a drug for the basic therapy of this disease, leads to a significant improvement in control, reduces the frequency of exacerbations of AD caused by viral infection in children aged 3-5 years. It has an anti-inflammatory effect, complementary to the action of glucocorticosteroids.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信